Cargando…
Capecitabine-Associated Loss of Fingerprints: A Case Report of a 62-Year-Old Man With Colorectal Cancer Suffering From Capecitabine-Induced Adermatoglyphia
Background: Capecitabine is a prodrug of 5-fluorouracil (5-FU) and is converted to 5-FU in tumor tissue. Its primary mechanism of action is the suppression of DNA synthesis via inhibition of thymidylate synthetase. It is mostly used for neoadjuvant chemoradiation, adjuvant chemotherapy for colorecta...
Autores principales: | Dawood, Tasneem, Zahir, Muhammad Nauman, Afzal, Muhammad, Rashid, Yasmin Abdul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265279/ https://www.ncbi.nlm.nih.gov/pubmed/34268045 http://dx.doi.org/10.7759/cureus.15519 |
Ejemplares similares
-
Capecitabine-Associated Loss of Fingerprints: Report of Capecitabine-Induced Adermatoglyphia in Two Women with Breast Cancer and Review of Acquired Dermatoglyphic Absence in Oncology Patients Treated with Capecitabine
por: Cohen, Philip R
Publicado: (2017) -
Adermatoglyphia in the Era of Biometrics
por: De, Abhishek, et al.
Publicado: (2022) -
Loss of Fingerprints as a Side Effect of Capecitabine Therapy: Case Report and Literature Review
por: Zhao, Jian, et al.
Publicado: (2020) -
Neoadjuvant Capecitabine and Oxaliplatin Before Concurrent Capecitabine and Radiation in Locally Advanced Rectal Cancers: Experience of a Cancer Hospital in Pakistan
por: Mansha, Muhammad Atif, et al.
Publicado: (2021) -
Is adermatoglyphia an additional feature of Kindler Syndrome?
por: de Almeida Jr, Hiram Larangeira, et al.
Publicado: (2015)